Celcuity Inc.CELC

時価総額

$37.5億

PER

バイオ医薬品開発の新興企業。PI3K/AKT/mTOR経路を標的とする抗がん剤候補gedatolisibの臨床開発を展開。Pfizerとのライセンス契約（2021年4月）と2022年12月の私募で約1億ドル、2024年5月の公募で約6000万ドルを調達。米国中心に展開。

概要財務

サマリーテーブルに戻る

	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-6,251,730	-7,480,815	-7,359,364	-9,474,175	-29,605,266	-40,370,040	-63,779,116	-111,779,105
Depreciation	104,704	223,037	338,996	385,591	303,235	210,918	142,772	129,947
Stock-based compensation	874,386	1	1	2	3	5	5	7
Amortization of debt issuance costs and discount	-	-	-	-	267,821	395,757	241,752	1
Payment-in-Kind interest	-	-	-	-	-	455,074	2	1
Non-cash operating lease, net	-	-	-	-	-	-	-	-434
Change in accrued interest income	-	-	-	-	-	-	-	-150,421
Other current assets	-	-	-	-	-	-	3	-775,981
Accounts payable	-262,507	25,432	45,617	52,971	1	1	2	4
Accrued expenses	392,315	-44,349	111,403	190,293	28,280	3	5	13
Net cash used for operating activities	-4,947,982	-6,076,269	-5,998,711	-7,145,689	-20,311,940	-36,008,171	-53,812,253	-83,466,743
Proceeds from maturities of investments	-	-	-	-	-	-	310	642
Purchases of investments	29	3	-	-	-	144	315	705
Purchases of property and equipment	239,848	629,608	380,201	-89,371	81,898	158,768	97,644	249,878
Net cash used for investing activities	-28,976,983	19	9	-89,371	-81,398	-144,031,794	-5,008,207	-63,069,283
Proceeds from exercise of common stock warrants	2,052	183,759	3,752	-	18,762	-	22,505	15
Proceeds from exercise of employee stock options	-	-	174,958	-	63,420	152,412	388,522	769,571
Proceeds from employee stock purchases	-	-	-	-	-	-	202,845	275,601
Proceeds from follow-on offering, net of underwriting discounts and offering costs	-	-	-	-	-	-	-	56
Proceeds from note payable, net of debt issuance costs and discount of $2,437,644	-	-	-	-	14	20	-	59
Proceeds from an ATM offering, net of issuance costs	-	-	-	-	-	-	-	7
Proceeds from pre-funded warrants, net of offering costs	-	-	-	-	-	-	50	-
Payments for secondary registration statement costs	-	-	-	-	-	-	45,805	227,405
Payments for debt issuance costs	40,961	-	-	-	-	-	2,716	-
Payments for finance leases	-	-	-	-	-	5,850	2,449	-
Net cash provided by financing activities	31	236,697	259,305	137,969	93	120	65	138
Net change in cash and cash equivalents	-	13	-	-	73	-59,714,824	6	-8,147,951
Interest paid	-	-	-	-	694,528	1	3	8
Deferred financing costs and offering and registration statement costs included in accounts payable	-	-	-	-	-	51,020	56,414	42,028
Property and equipment included in accounts payable	-	-	-	-	-	-	13,615	1,417
Common stock warrants issued with the note payable transaction	-	-	-	-	-	-	-	1